Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Inflarx

Evaluate

Thumbnail
August 30, 2022

Kymera’s pain could be Priovant’s gain

Pfizer’s Irak-4 inhibitor PF-06650833 definitely, definitely doesn’t work in hidradenitis suppurativa, but there’s at least partly better news for Priovant.

Thumbnail
April 07, 2021

Second-quarter catalysts for the smaller players

Key catalysts approach for Orphazyme, Gemini and Immutep.

Article image
Vantage logo
March 05, 2021

Apellis fails to complement severe Covid-19

Article image
Vantage logo
October 29, 2020

Chemocentryx takes a leap of faith with avacopan

Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.

Article image
Vantage logo
October 08, 2020

Mapping the transatlantic divide for biotech flotations

A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.

Article image
Vantage logo
November 26, 2019

Chemocentryx soars on superior avacopan

With data showing superiority over glucocorticoids, Chemocentryx could have a new standard of care for vasculitis in avacopan.

Article image
Vantage logo
October 04, 2019

Japanese drugmakers stand out at the nine-month mark

Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.

Article image
Vantage logo
August 16, 2019

Upcoming events – Rare disease data due from Chemocentryx and Sanofi

Chemocentryx and Sanofi are looking to target the complement pathway in ANCA-associated vasculitis and cold agglutinin disease respectively, with phase III data due in…

Article image
Vantage logo
July 19, 2019

Inflarx pushes past the red flags to claim a win

Article image
Vantage logo
July 05, 2019

Cannabis, M&A and data spur strong gains among small and midcaps

The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…

Vantage logo
July 03, 2019

Share price catalysts: June 2019

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up